At a glance
ClinicalIndex Comparison Record- ✓Adults aged >18 years
- ✓Symptomatic HF (Stage C) diagnosed within 6 months of decompensated HF episode treated by hospital admission or outpatient clinic
- ✓LVEF <40% (HFrEF) or LVEF ≥50% (HFpEF) on baseline echocardiography
- ✓Available for follow-up over 3 years
- ✕Severe valve disease as the primary cause of HF
- ✕For HFpEF cohort: prior documented LVEF <50% at any time before recruitment
- ✕Life-threatening comorbidity with life expectancy <1 year
- ✕Concurrent participation in a clinical therapeutic trial requiring patient consent
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Asian Sudden Cardiac Death in Heart Failure(ASIAN-HF) Prospective Observational Study
In Brief
An observational study evaluating Saliva Genetic testing for Heart Failure. Completed, enrolled 6,329 participants across 11 sites in 11 countries.
Detailed Summary
The ASIAN HF Registry is the first prospective multinational Asian registry of patients with symptomatic HF (stage C) including both HFrEF (ejection fraction \<40%) and HFpEF (ejection fraction ≥50%), with the broad purpose of determining the mortality (incidence) burden of HF in Asian patients, and more specifically to define the burden and risk factors of Sudden Cardiac Deaths (SCD), as well as the sociocultural barriers to preventive device therapy. The study further aim to study the genetic variants associated with HFrEF versus HFpEF in our large Asian cohort. This proposed registry is expected to advance fundamental understanding of the burden and predictors of preventable death among Asian patients with HF. The knowledge gained will be critical for guiding resource allocation and planning preventive strategies to address the unmet and growing clinical needs of patients with cardiovascular disease in Asia.
Study Details
Timeline
Interventions
To compare the genetic variants between the two phenotypes of reduced versus preserved ejection fraction (HFrEF versus HFpEF)